Inotuzumab ozogamicin (Besponsa)

At a glance

Inotuzumab ozogamicin (Besponsa) is an antibody–drug conjugate, often shortened to ADC. It combines an antibody that recognises a target on cells with a cell-killing medicine. It is given by a trained team through a drip into a vein. Although it is targeted treatment, it can affect healthy tissues and needs careful monitoring.

Besponsa requires careful liver monitoring, especially when stem-cell transplantation is being considered. It is often delivered in weekly divided doses within a cycle. The number of cycles and any later transplant are planned together to balance cancer control and treatment-related harm.

Follow your own treatment calendar and the advice from your care team. Keep your medicine names and treatment dates handy to share with other clinicians.

How it works

Inotuzumab recognises CD22, a protein on certain B cells. The attached calicheamicin derivative damages DNA after the conjugate enters the cell. The treatment can kill target cells but can also suppress normal blood-cell production and injure the liver. It is distinct from CD19-directed T-cell engagers and CAR T-cell therapy.

The antibody, its chemical link and the attached medicine form one product. They are not separate medicines that you can take in different amounts yourself. Targeting helps deliver treatment to particular cells, but it does not mean that only cancer cells are affected. Side effects can come from the attached medicine, the antibody, your existing illness or accompanying treatment.

An ADC is different from an immune checkpoint inhibitor, even when both are given in the same treatment plan. A reaction or noticeable side effect is not proof that an ADC is working. Equally, having few side effects does not mean that treatment has failed.

Is this treatment suitable for me?

Inotuzumab ozogamicin is used for selected relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL). Previous treatment and disease features, including Philadelphia chromosome/BCR-ABL status, help determine eligibility; paediatric eligibility needs specialist assessment. Your oncologist will advise whether it is suitable for you, taking account of your cancer type, relevant test results, previous treatment, overall health and the applicable prescribing information and regulatory guidance in your country.

The team checks CD22-related findings, prior treatment, liver health and transplant plans. A history of severe liver disease or sinusoidal obstruction syndrome is particularly important. European information contraindicates treatment after confirmed severe or ongoing VOD and with serious active liver disease such as cirrhosis, nodular regenerative hyperplasia or active hepatitis. Heart-rhythm problems and medicines that prolong the QT interval also need review. The goal of treatment, including whether it is intended to prepare for transplantation, affects duration.

The discussion should cover the aim of treatment, the alternatives, likely appointments and how benefit will be assessed. A target found in a sample is one part of this decision; it does not guarantee a response. Tell the team what matters to you, including independence, work, caring responsibilities and the practical support available at home.

Before treatment

Bring a complete list of prescribed and non-prescribed medicines, vitamins, herbal products and allergies. Mention previous difficult reactions to infusions, infections, diabetes, liver or kidney problems and any pregnancy or breastfeeding. Explain symptoms you already have so a later change is easier to recognise.

Tests include blood counts, liver function, kidney function, blood salts and a baseline ECG. Pregnancy testing is needed if you could become pregnant. The team reviews earlier liver injury, transplants, conditioning medicines and current infection. A high circulating disease burden may need reduction before the first dose. Baseline weight and abdominal findings help detect later fluid retention or liver changes.

A nurse or pharmacist should explain the supportive medicines and which ones start before the treatment day. Ask your team to help you plan when to take each medicine. Make sure you know how to reach your hospital's urgent oncology service outside clinic hours. You may find it helpful to save the instructions on your phone or keep a copy at home. A family member or friend can help you remember them.

Discuss fertility preservation before treatment if future parenthood matters to you. Tell the team about dental problems and planned procedures. A procedure may need to be timed around blood counts and infection risk. Do not postpone reporting an active dental infection while waiting for the next routine appointment.

How treatment is given

Besponsa is infused over one hour, usually on days 1, 8 and 15 of a cycle. A standard first-cycle total is 1.8 mg/m², split as 0.8 mg/m² then 0.5 mg/m² on each of the next two dosing days. Later doses depend on response: the total may reduce to 1.5 mg/m², divided equally across the three days. The first cycle is generally three weeks, sometimes extended to four; subsequent cycles are usually four weeks. The specialist determines the exact schedule and any necessary pauses.

A corticosteroid, fever-reducing medicine and antihistamine are given before dosing. Observation continues for at least one hour after the infusion. For someone proceeding to stem-cell transplant, the usual recommended course is two cycles; a third may be considered in specified circumstances. Patients not proceeding to transplant may receive additional cycles, up to six under the checked instructions. Treatment should stop if complete remission, with or without full blood-count recovery, has not been achieved within three cycles. These limits are clinical decisions, not a target to reach regardless of response or toxicity.

Treatment is delivered through a cannula in a vein, a central line or an implanted port, depending on the plan and available access. Staff check the medicine, your identity, blood results and recent symptoms before starting. The appointment includes preparation and monitoring, so it will usually take longer than the infusion itself.

Tell the nurse immediately if you notice burning, pain, swelling, redness, leakage or tightness around the infusion site. These can mean medicine is leaking outside the vein. Do not wait for the drip to finish. At home, report a site that becomes more painful, blistered or discoloured, even if it looked normal when you left.

Also report flushing, itching, shivering, chest or back discomfort, wheezing, dizziness or swelling during treatment. Staff can stop or slow the infusion and assess you. Do not adjust the pump or line yourself. If a line remains in place, follow its cleaning and dressing instructions and report fever, tenderness or drainage around it.

If an appointment is missed, contact the treatment unit to arrange the next dose. Do not simply wait for the following cycle or seek an extra dose elsewhere. The correct restart date depends on why the dose was missed, the treatment schedule and recovery from side effects.

Monitoring your treatment

Blood tests usually check infection-fighting cells, red cells, platelets, kidney function and liver function. Some abnormalities cause no early symptoms. A reassuring blood test does not make a new symptom safe to ignore, and feeling well is not a reason to miss monitoring.

Liver tests are checked before and after each dose. US instructions specify at least weekly liver tests during the first month after transplant, followed by ongoing monitoring. Blood counts guide infection and bleeding support. ECGs and blood salts are assessed before treatment and periodically during treatment because the QT interval can be prolonged. They should also be checked when a QT-prolonging medicine is started. European information additionally recommends monitoring pancreatic enzymes, amylase and lipase. Response is assessed using the appropriate blood and marrow tests, including testing for small amounts of residual disease when relevant. A good cancer response does not remove the risk of transplant-related complications.

Your team compares examinations, symptoms and relevant scans or disease tests over time. Ask when the first response assessment is planned and what the result could change. A treatment break or lower dose may protect you from accumulating harm while allowing further treatment. It is not automatically evidence that the cancer has worsened. Never try to compensate for a reduced dose with supplements or closer appointments.

Common side effects

Side effects vary between people and between treatment combinations. You may experience several, a few or none of those described. Tell the team about symptoms that interfere with eating, sleeping, walking or usual tasks; a problem does not need to be severe before support is worthwhile.

Low blood counts, fever and bleeding

White cells, platelets and red cells can fall. Infection, fever, bruising, nosebleeds and fatigue need active attention. Follow blood-test and transfusion appointments and report symptoms promptly. A fever may occur with an infusion, but a fever at home still needs assessment for infection.

Headache and digestive symptoms

Headache, nausea, vomiting and abdominal discomfort can occur. Use the prescribed supportive medicines and maintain intake as tolerated. A new severe headache, especially with low platelets or neurological changes, should not be treated as a routine headache. Persistent or right-sided upper abdominal pain needs assessment for liver complications.

Tiredness and reduced stamina

Plan important tasks for the part of the day when you have most energy and accept practical help. Short periods of gentle activity can be useful, with rest between them. Sudden marked weakness, breathlessness, dizziness or a racing heart needs assessment for causes such as anaemia, infection or dehydration. Do not assume every new limitation is ordinary treatment fatigue.

Nausea, appetite and bowel changes

Take prescribed anti-sickness medicines on the agreed schedule. Small regular meals, cool foods and frequent sips can be easier to manage. Tell the team if you cannot keep medicines or fluids down, are passing little urine or are losing weight. A dietitian can help when eating becomes difficult.

Record loose stools and whether there is pain, blood or fever. Severe diarrhoea, repeated vomiting or a swollen painful abdomen needs prompt advice. Constipation can be worsened by anti-sickness drugs and pain relief; use the bowel plan your team recommends. Do not repeatedly add laxatives or anti-diarrhoeal medicines without checking when there is significant pain or other new illness.

Low blood counts

A low white cell count can make infection progress quickly. Follow the urgent-help instructions below. Low red cells can cause tiredness, pallor or breathlessness; sometimes transfusions are needed. Low platelets can cause easy bruising, nosebleeds, bleeding gums or tiny red-purple spots. Report new bleeding and avoid starting aspirin or anti-inflammatory painkillers without checking. Do not stop a prescribed blood thinner yourself; the team must balance bleeding and clotting risks.

Mouth comfort and skin care

Use a soft toothbrush and the mouth-care products advised by your team. Report ulcers, white patches or soreness that limits eating, because infection or dehydration may need treatment. Avoid very hot, acidic or spicy foods if they sting. Moisturise dry skin with a simple fragrance-free product and protect it from strong sunlight. Painful skin, blisters or rapidly worsening redness need medical assessment rather than a new cosmetic product.

Important side effects

Liver injury and sinusoidal obstruction syndrome

Also called veno-occlusive disease, this is a potentially life-threatening problem in the small blood vessels of the liver. It can occur with Besponsa, after the medicine has finished and after a later transplant. Rapid weight gain, abdominal swelling, pain beneath the right ribs, jaundice or reduced urine needs urgent attention. Confirmed VOD or other severe liver toxicity requires permanent discontinuation.

Complications around stem-cell transplantation

Besponsa exposure is associated with increased risk of death from causes other than relapse after transplantation, including liver complications and infections. The team considers this when choosing the number of cycles, transplant timing and conditioning drugs. Conditioning with two alkylating medicines increases VOD risk and should be avoided where possible; the transplant team must assess any unavoidable exception. Make sure the transplant centre knows about every cycle, even if treatment was given at another hospital.

Heart-rhythm disturbances and tumour lysis

QT prolongation can increase the risk of an abnormal heart rhythm. Palpitations, near-fainting or collapse needs urgent assessment, especially with vomiting or diarrhoea that can disturb blood salts. Rapid cancer-cell breakdown can also affect the kidneys and salts; take prescribed preventive medicines and report reduced urine, cramps or confusion promptly.

Severe infection or an allergic reaction

A serious infection can occur even without a high temperature, especially if steroids or fever-reducing medicines are being taken. New confusion, marked drowsiness, rapid breathing or collapse requires emergency care. Sudden throat swelling, severe wheezing or faintness can indicate a severe allergic reaction. These symptoms should not be managed by waiting at home for the next scheduled review.

Other medicines and vaccinations

Review medicines that prolong the QT interval, including certain anti-sickness medicines, antibiotics, antifungals and heart-rhythm treatments. The team may choose alternatives or increase ECG and electrolyte monitoring. Transplant-conditioning drugs and other liver-toxic medicines need coordinated specialist review. Do not start or stop them without a treatment plan.

Ask the oncology pharmacist to check new prescriptions, over-the-counter remedies and herbal or traditional products. Products described as natural are not necessarily safe with cancer treatment. Do not use an unproven supplement in place of an essential supportive medicine. Keep the team informed about medicines prescribed by other specialists so that advice is coordinated.

Discuss influenza, COVID-19 and other vaccines with the team. Non-live vaccines may be suitable, although the response can be reduced during treatment. Live viral vaccines are not recommended for at least two weeks before Besponsa, throughout treatment and until B lymphocytes recover after the last cycle. The team should confirm recovery and vaccine timing. Timing after treatment depends on immune recovery and the complete regimen; there is no single waiting interval that is correct for every ADC-treated patient.

Everyday life

Eating does not determine absorption of this intravenous medicine. Aim for enough food and fluids, adjusting for nausea and following any kidney, heart or diabetes restrictions. Avoid a restrictive anticancer diet that causes weight loss. Discuss alcohol with the team, particularly if liver tests are abnormal or other medicines cause sedation.

Work may remain possible with flexible hours and time for appointments. Increase activity gradually and avoid tasks that become unsafe because of fatigue, poor balance or impaired vision. Do not drive if dizzy, sleepy, visually affected or unable to use the pedals safely. Sedating premedicines can also affect driving, so arrange transport for early appointments until you know the plan.

Keep a single calendar for infusions, blood tests, transfusions, supportive medicines and transplant appointments. During low counts, avoid activities with a high risk of injury and follow the centre’s infection precautions. Report a rapid increase in weight or tighter abdominal clothing if fluid retention is suspected.

Discuss travel before booking, especially long journeys or travel far from urgent care. Carry your treatment summary and enough supportive medicines. Use careful hand hygiene and food safety; avoid close contact with people who are clearly infectious. Complete social isolation is not automatically required. Ask about additional precautions when blood counts are very low.

Sex is often possible if comfortable, with the pregnancy precautions below and any advice about infection or bleeding. Ask the team whether barrier protection is needed after a dose to reduce exposure to drug residues in body fluids; the interval depends on the treatment. Caregivers cleaning urine, stool or vomit should follow the unit's handling advice, wear gloves when instructed and wash their hands afterwards. Keep medicines away from children and pets.

Fertility, pregnancy and breastfeeding

Use effective contraception during treatment and for at least eight months after the final dose if you could become pregnant. A treated man with a partner who could become pregnant should use effective contraception during treatment and for at least five months afterwards. Do not breastfeed during treatment or for at least two months after the final dose. Transplantation and other therapies can require additional precautions and can have major effects on fertility.

Pregnancy should be discussed before treatment and reported promptly if it occurs or is suspected. Loss of periods does not reliably mean pregnancy is impossible. Vomiting or severe diarrhoea can interfere with oral contraception; seek advice about additional protection if this happens. Accompanying medicines may require longer precautions than the ADC itself, so obtain one clear end date for the complete regimen.

Fertility may be affected by treatment and previous therapies, and recovery cannot be guaranteed. Discuss sperm, egg or embryo preservation before starting when feasible. The interval for avoiding pregnancy is a safety precaution and does not itself establish whether fertility has recovered.

After treatment

Continue liver surveillance and blood-count monitoring for the period specified by the team. A transplant does not erase the relevance of earlier Besponsa exposure. The transplant service should have dose dates, response results and details of any liver or infectious complications.

Keep attending the recommended blood tests, scans and clinical reviews. Retain a treatment summary with the exact ADC name, dates, significant reactions and any ongoing medication. Tell new clinicians about past treatment when an unexplained symptom is assessed. Continue contraception, breastfeeding restrictions and prescribed supportive medicines for their own specified periods, counted from the relevant final dose.

Recovery can be gradual and may involve physical rehabilitation, dietary support or help with anxiety and sleep. A follow-up visit is also an opportunity to discuss returning to work, travel and persistent symptoms. New severe symptoms still need urgent assessment between appointments; finishing treatment does not remove the need for the urgent-care plan.

Common questions